Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients

Recruiting in Palo Alto (17 mi)

Overseen byMichael Farris, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this research study is to find out what effects (good or bad) may come from a new way of doing radiation therapy for lung cancer. This study is for patients who are not able to get surgery or chemotherapy with their radiation. The way of doing radiation therapy in this trial is called hypofractionated radiation therapy which is a standard approach, but this study allows the actual tumor to get an extra radiation dose while still protecting the organs that are near the tumor.

Research Team

Michael Farris, MD

Principal Investigator

Wake Forest University Health Sciences

Eligibility Criteria

Inclusion Criteria

Ultracentral disease will be defined as edge of gross visible tumor within 1.0 cm of the proximal bronchial tree.

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3

Participant is not eligible for or has declined surgical resection or stereotactic body radiotherapy as determined by the treating physician

See 6 more

Treatment Details

Interventions

Hypofractionated Radiation Therapy (Radiation Therapy)
Radiation Boost (Radiation Therapy)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Hypofractionated Radiation TherapyExperimental Treatment2 Interventions

Hypofractionated radiation therapy will be delivered to all participants. The radiation will be planned in a special way to give the biggest parts of the tumors that are the most difficult to control a little more radiation every day than the lower risk areas.

Hypofractionated Radiation Therapy is already approved in Canada for the following indications: